Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02140372 · ClinicalTrials.gov registry record · Phase 4
Anti-platelet Effects of Colchicine in Healthy Volunteers
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02140372 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants.
The verdict
NCT02140372, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug administration, 2 hours after colchicine administration, and 24 hours after colchicine administration via the antecubital vein and evaluated for markers of platelet activity and inflammation.
Interventions
- DRUG Colchicine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02140372
The ClinicalTrials.gov registry entry for NCT02140372 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Colchicine is the first listed.
NCT02140372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02140372 about?
NCT02140372 is a clinical study titled "Anti-platelet Effects of Colchicine in Healthy Volunteers". This is a pilot study. Volunteers will be given 1.8 mg (1.2 mg followed by 0.6 mg one hour later), 1.2 mg, or 0.6 mg of colchicine. Blood will be collected prior to drug administration, 2 hours after colchicine administration, and 24 hours after colchicine administration via the antecubital vein and...
What is the current status of trial NCT02140372?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2014-05. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02140372?
The interventions under investigation include: Colchicine (DRUG).
Who is sponsoring clinical trial NCT02140372?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.